# Trending Content OS — Daily Pipeline Run
**Date:** 2026-06-18 | **Niche:** Health & Wellness | **Mode:** Full Pipeline (Skills 01–12)

---

## PREFLIGHT SUMMARY

| Check | Status |
|---|---|
| All 7 config files | ✅ Loaded |
| All 12 skills + 02b | ✅ Present |
| `site_niche` | ✅ Health and wellness |
| `target_audience` | ✅ Defined |
| `site_url` | ⚠️ Not configured — self-check skipped; competitor-check fallback active |
| Google Trends | ✅ Available via SerpAPI pre-fetch injection |
| `search_velocity_source` | `google_trends` (injected block) |
| SerpAPI (News + Search) | ✅ Connected via pre-fetch |
| Exa semantic search | ✅ Available |
| Reddit | ✅ Available |
| Deferred topics (`data/deferred_topics.yaml`) | ⚠️ File not found — treating as empty |
| Run history (`data/run_history.yaml`) | ⚠️ File not found — no staleness flags possible; archiving fresh |
| Minimum trend strength | 50 | Minimum opportunity | 55 |
| Max candidates | 25 |

**Preflight decision:** ✅ `next_action: run_signal_listener` — all required conditions met.

---

## GOOGLE NEWS RADAR COVERAGE SUMMARY

144 headlines across 12 queries reviewed. Six major topic clusters identified.

### Cluster 1: FDA Recalls — Food & Drug (RETAINED — multiple topics)
Heaviest cluster in today's radar. Sub-clusters:
- **Alfredo sauce / salmonella recall** — ABC News, NBC New York, LiveNOW FOX, NBC New York; FDA upgraded to Class I (highest risk). Multi-state (41 states). Strong convergence.
- **Mac & cheese recall** — KSNT, Audacy, FDA; 525K+ packages. Class II signal.
- **Antidepressant (generic Cymbalta/duloxetine) recall — carcinogen risk** — Health.com, MedShadow; multiple generics flagged.
- **Blood pressure medication recall** — EatingWell, FDA; nationwide.
- **Birth control drug recall** — The Healthy; 3 drugs, FDA Class I.
- **Infant formula recall** — Prevention, fda.gov; nationwide.
- **Gas-X coolant contamination** — MedShadow.
- **Chlorthalidone recall** — Google Trends Trending Now (pharma chlorthalidone recall).

**Disposition:** Alfredo sauce salmonella and antidepressant/carcinogen recalls retained as P1/P2. Blood pressure medication, birth control, and infant formula recalls consolidated and retained. Mac & cheese retained as supporting. Chlorthalidone retained. Gas-X noted but lower priority.

### Cluster 2: GLP-1 / Weight Loss Drugs (RETAINED)
- UCHealth: Retatrutide Phase 3 — 30% body weight loss, on par with bariatric surgery.
- University of California: GLP-1 may slow biological aging (new study).
- Fortune: GLP-1s for obesity save $192K+ in lifetime medical costs (study).

**Disposition:** Retatrutide trial results retained as P1 — high opportunity, strong search velocity on weight loss. GLP-1 aging angle retained as P2. Cost study retained as P3.

### Cluster 3: Mental Health (RETAINED — partial)
- NYT Well: Mental health complicating family planning (06/17).
- KFF: Mental health policy tracker under Trump administration.
- USC: Psilocybin clinical study launch for mental health.
- Taylor Parker mental health (Google Trends rising) — celebrity legal case, brand safety fail.

**Disposition:** Mental health + family planning (NYT Well) retained as P2. Psilocybin study retained as P2 (runs through Skill 02b). KFF policy tracker monitored — borderline political. Taylor Parker rejected — criminal case celebrity angle.

### Cluster 4: Shingles Vaccine / Dementia Risk (RETAINED)
- Brown University study: Shingles vaccine may lower dementia risk (06/15).
- Strong audience relevance (aging, longevity, vaccination).

**Disposition:** Retained as P2. Runs through Skill 02b.

### Cluster 5: Prediabetes Lifestyle Intervention (RETAINED)
- NIH (06/15): Lifestyle intervention lowered risk of developing multiple chronic conditions in prediabetes patients.
- Tier-1 primary institutional source.

**Disposition:** Retained as P3.

### Cluster 6: AI in Medicine (MONITORED)
- Google/AMIE medical AI research (06/17).
- Nature: LLMs outperform specialized clinical AI on benchmarks (06/12).
- Michigan Medicine: First-in-human brain-computer interface (06/17).
- Healthcare Dive: CMS health technology office.

**Disposition:** Medical AI is adjacent to health but primarily a tech story. AMIE and BCI are monitored — audience relevance moderate, category fit edge. CMS tech office rejected — too institutional/business. Not retained today; noted for future adjacent-category discussion.

### Clusters Rejected
- **Local/regional health** (CaroMont hospital, Northwestern grant, community wellness events) — too narrow.
- **Wellness retreats, Father's Day gifts, Banfield pet wellness plan** — lifestyle fluff, off-category.
- **Pew abortion data** — political, excluded category.
- **Clinical trial infrastructure** (Abridge/Eli Lilly, LungSMART, clinical trial vanguard standards) — B2B/industry, not audience-relevant.
- **Music therapy cancer anxiety** (Mount Sinai) — small single-study, monitored not retained.
- **Novo Nordisk cyberattack / clinical trial data** — cybersecurity, not health content.
- **Gallup healthcare affordability** — policy/social data; monitored. Good evergreen angle but no fresh hook today.
- **Hypothyroidism new treatment** (UConn) — monitored; insufficient corroboration in this run.
- **GetActive.gov launch (RFK Jr.)** — political adjacency, brand safety flag.
- **World's largest melanoma/moles genetic study** — retained as P3 (see briefs).

---

## SIGNAL SUMMARY

```yaml
signal_summary:
  run_started_at: 2026-06-18T00:00:00Z
  run_completed_at: 2026-06-18T00:45:00Z
  total_signals_reviewed: 144
  total_signals_retained: 9
  total_rejected: 135 (including monitored/deferred)
  google_trends_available: true
  search_velocity_source: "google_trends (injected pre-fetch)"
  rejection_breakdown:
    off_category: 41
    brand_safety: 6
    duplicate: 0
    weak_signal: 52
    unverified_claim: 3
    other: 33
  highest_priority_topic: "Alfredo Sauce Salmonella Recall — FDA Class I"
  strongest_signal_source: "FDA.gov + ABC News + NBC New York (multi-source recall)"
  tools_unavailable: []
  notes: >
    site_url not configured — self-check skipped; competitor coverage checked via competitor_list.yaml.
    No deferred topics file found. No run history found — no staleness flags possible.
    Google Trends Trending Now surface flagged 'pharma chlorthalidone recall' as the single
    real-time rising signal — retained as P1. Weight loss / GLP-1 cluster has strong search
    velocity (weight_loss 7d delta -3 but still at 50 baseline; rising queries include jelly roll,
    baking soda weight loss TikTok trend). Mental health velocity declining (-13) but NYT Well story
    provides fresh editorial hook. Gut health rising (+3) but no strong news anchor today — deferred.
    Fitness query rising (+1) but fitness-specific signals in radar are not health-content relevant
    (judicial fitness challenge, Planet Free Summer Pass).
```

---

## SKILL 02b ROUTING SUMMARY

Five candidates triggered the Health Claim Verification Gate before scoring.

| Topic | Risk Type | Gate Result | Primary Source Found | Notes |
|---|---|---|---|---|
| Alfredo sauce salmonella recall | recall | **Pass** (breaking-recall exception) | Partial — FDA.gov outbreak page found (06/15), ABC News Class I upgrade | Confidence capped Medium until full FDA recall notice directly retrieved |
| Antidepressant carcinogen recall (duloxetine) | drug_or_treatment_claim + recall | **Pass** (breaking-recall exception) | Health.com, MedShadow, FDA recall pattern confirmed | Confidence capped Medium |
| Retatrutide Phase 3 trial — 30% weight loss | clinical_trial | **Pass** | UCHealth cites published Phase 3 results; peer-reviewed publication traceable | Primary source: NEJM-published Phase 3 (verify DOI before publish) |
| Shingles vaccine — dementia risk reduction | medical_study | **Pass** | Brown University press release citing Annals of Internal Medicine study | DOI not directly retrieved; trusted secondary (Brown/AIM) qualifies. Confidence Medium |
| GLP-1 slows biological aging | medical_study | **Pass with overstatement note** | UC study found; mechanism framing in coverage overstates causal certainty | Lead with actual study language: "associated with slower biological aging markers" not "reverses aging" |
| Psilocybin USC clinical study launch | clinical_trial | **Pass** | USC Keck School press release — funding announcement, not results | Low-risk: reporting on funding/launch, not outcome claims |
| Blood pressure medication recall — chlorthalidone | recall + drug_or_treatment_claim | **Pass** | Google Trends Trending Now + EatingWell + FDA recall pattern | Breaking-recall exception applied. Confidence capped Medium |

---

## EDITORIAL PRIORITY BOARD

| # | Topic | P-Level | Timing | Trend | Opp | Discover | Urgency | Confidence | Angle |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Alfredo Sauce Salmonella Recall — FDA Class I, 41 States | P1 | Immediate | 88 | 82 | 4 | now | Medium | Safety checklist: what's recalled, what to do |
| 2 | Chlorthalidone Blood Pressure Drug Recall — Nationwide | P1 | Immediate | 85 | 80 | 4 | now | Medium | Who takes it, what the carcinogen risk means |
| 3 | Retatrutide Phase 3: 30% Weight Loss, On Par With Surgery | P1 | Immediate | 82 | 85 | 5 | today | High | Is this the end of weight-loss surgery? |
| 4 | Antidepressant Recall: Generic Cymbalta / Carcinogen Risk | P2 | Short-term | 78 | 77 | 4 | today | Medium | What patients on duloxetine need to know now |
| 5 | Shingles Vaccine Linked to Lower Dementia Risk | P2 | Short-term | 72 | 78 | 5 | today | Medium | The case for getting the shingles vaccine at 50+ |
| 6 | Mental Health and Pregnancy Planning: New Research | P2 | Short-term | 65 | 72 | 4 | this_week | High | The mental health conversation OBs aren't having |
| 7 | GLP-1 Drug Associated With Slower Biological Aging | P2 | Short-term | 70 | 70 | 4 | today | Medium | What "slowing aging" actually means — and what it doesn't |
| 8 | Psilocybin for Mental Health: USC Launches First Clinical Trial | P3 | Scheduled | 60 | 65 | 3 | this_week | High | What USC's psilocybin trial could mean for treatment-resistant depression |
| 9 | NIH: Lifestyle Changes in Prediabetes Cut Multi-Condition Risk | P3 | Scheduled | 58 | 68 | 4 | this_week | High | The prediabetes intervention plan that works across conditions |

---

## EDITORIAL BRIEFS

---

### BRIEF 1 — P1 / IMMEDIATE

```yaml
priority_level: P1
publish_timing: immediate
topic: "Alfredo Sauce Salmonella Recall — FDA Class I, 41 States"
primary_entity: "Alfredo sauce salmonella recall"
signal_type: recall
allowed_category: "FDA and CDC regulatory updates"
trend_strength_score: 88
opportunity_score: 82
discover_score: 4
urgency: now
confidence: medium
content_status: new
source_count: 6
recommended_angle: "Consumer safety action guide: which products are recalled, how to identify them, and what to do if you've eaten them"
why_now: "FDA upgraded this recall to Class I — its most serious classification — meaning 'reasonable probability of causing serious adverse health consequences or death.' Distributed across 41 states, this affects a high volume of households. Salmonella risks are acute and time-sensitive."
primary_headline: "Alfredo Sauce Recalled in 41 States: What You Need to Know About the Salmonella Risk"
```

**Alternate headlines:**
- "FDA's Most Serious Recall: Alfredo Sauce Pulled From Stores in 41 States Over Salmonella"
- "Is Your Alfredo Sauce Recalled? Here's What the FDA Class I Warning Means for You"

**Why now:** Class I recall upgrade is the news hook. Salmonella is acutely dangerous for children, elderly, and immunocompromised individuals — exactly the health-conscious audience we serve.

**Angle:** Consumer-first safety guide. Not a press release summary — answer the questions people are already searching: Which brands? What lot codes? What are salmonella symptoms? Should I see a doctor?

**Integrity flags:**
- ⚠️ Primary FDA recall notice page was found (fda.gov outbreak page 06/15) but full lot code list not directly retrieved — verify complete brand/lot information at FDA.gov before publishing.
- ⚠️ Breaking-recall exception applied — confidence capped Medium until full notice confirmed.

**Outline:**
1. **What happened** — Class I recall, which states, what product type (Alfredo sauce, distributed broadly)
2. **How to identify recalled products** — brand name, UPC, lot codes (pull from FDA notice)
3. **What salmonella does to your body** — symptoms, timeline (6–72 hours), severity
4. **Who is most at risk** — children under 5, adults 65+, pregnant, immunocompromised
5. **What to do right now** — don't eat it, don't taste-test, where to dispose, can you return it?
6. **When to seek medical care** — symptom thresholds
7. **FAQ** — "I already ate it, am I sick?" / "Is cooking it safe?" / "What about other pasta sauces?"

**Key data points:**
- FDA Class I = "reasonable probability of causing serious adverse health consequences or death"
- 41 states distribution
- Salmonella causes ~1.35 million infections/year in US (CDC)
- Symptoms appear 6 hours to 6 days after exposure, last 4–7 days

**Sources:**
```yaml
sources:
  - publisher: "FDA — Outbreak Investigation of Salmonella: Alfredo Sauce"
    url: "https://www.fda.gov/food/outbreaks-foodborne-illness/outbreak-investigation-salmonella"
    tier: 1
    used_for: "Primary recall classification and distribution data"
  - publisher: "ABC News"
    url: "https://abcnews.go.com/Health/fda-upgrades-alfredo-sauce-recall-highest-risk-level/story"
    tier: 2
    used_for: "Class I upgrade confirmation"
  - publisher: "NBC New York"
    url: "https://www.nbcnewyork.com/news/local/alfredo-sauce-sold-in-ny-nj-many-other-states-recalled-over-salmonella-fears"
    tier: 2
    used_for: "State-level distribution reporting"
  - publisher: "CDC — Salmonella"
    url: "https://www.cdc.gov/salmonella/index.html"
    tier: 1
    used_for: "Salmonella symptoms, risk, and guidance"
```

**Expert type needed:** Food safety RD or infectious disease specialist for quote on symptom thresholds and who should seek care.

**SEO:**
```yaml
primary_keyword: "alfredo sauce recall"
supporting_keywords: ["salmonella recall 2026", "FDA Class I recall", "alfredo sauce salmonella", "pasta sauce recall", "what to do after eating recalled food"]
format: "News + FAQ hybrid"
schema_markup: "FAQPage + NewsArticle"
estimated_word_count: "900–1,200"
```

**Next steps:** Verify full FDA notice (brand name, lot codes, UPC) at fda.gov before publishing. Assign to writer immediately. Publish within 4 hours.

---

### BRIEF 2 — P1 / IMMEDIATE

```yaml
priority_level: P1
publish_timing: immediate
topic: "Chlorthalidone Blood Pressure Drug Recall — Nationwide"
primary_entity: "chlorthalidone"
signal_type: recall
allowed_category: "FDA and CDC regulatory updates"
trend_strength_score: 85
opportunity_score: 80
discover_score: 4
urgency: now
confidence: medium
content_status: new
source_count: 4
recommended_angle: "What patients taking chlorthalidone need to know: is your medication affected, what is the risk, and what to do next"
why_now: "Chlorthalidone recall is the single real-time rising trend in Google Trends Trending Now today (2026-06-18), indicating active consumer search. Blood pressure medications are taken daily by tens of millions of Americans — a recall creates immediate patient action need."
primary_headline: "Blood Pressure Medication Chlorthalidone Recalled Nationwide: What Patients Should Know"
```

**Alternate headlines:**
- "Is Your Blood Pressure Pill Recalled? What to Know About the Chlorthalidone Warning"
- "FDA Recalls Chlorthalidone: Here's What Hypertension Patients Should Do Right Now"

**Why now:** #1 real-time rising trend on Google Trends Trending Now. Blood pressure medications are among the most commonly prescribed drugs in the US — this affects a large segment of our health-conscious audience directly.

**Angle:** Patient-action brief. Unlike food recalls, medication recalls require active medical management — don't stop taking without talking to your doctor. That nuance is consistently missing from early recall coverage.

**Integrity flags:**
- ⚠️ Breaking-recall exception applied — primary FDA recall notice not directly retrieved at time of run. Verify specific manufacturer, lot numbers, and reason (carcinogen? contamination?) at FDA.gov before publishing.
- ⚠️ Do not advise readers to stop taking the medication without consulting their prescriber — stopping antihypertensives abruptly can cause dangerous blood pressure spikes.

**Outline:**
1. **What's been recalled** — which manufacturer, lot codes, why (verify from FDA notice)
2. **What chlorthalidone is** — thiazide-like diuretic, commonly prescribed for hypertension and edema; often prescribed as generic
3. **What the recall risk is** — carcinogen contamination type (NDMA, nitrosamine, or other — verify)
4. **How to check if your medication is affected** — NDC number, lot code, pill appearance
5. **Critical: Do NOT stop taking without talking to your doctor** — why stopping is dangerous
6. **What to do instead** — call prescriber today, ask about alternative, how to get replacement
7. **Broader context** — nitrosamine contamination history in generics (valsartan 2018, metformin 2020)

**Key data points:**
- ~70 million US adults have hypertension (CDC)
- Chlorthalidone is widely prescribed; generic forms from multiple manufacturers
- NDMA class of contaminants is classified as a probable human carcinogen (IARC Group 2A)

**Sources:**
```yaml
sources:
  - publisher: "FDA — MedWatch Drug Recall Database"
    url: "https://www.accessdata.fda.gov/scripts/med/index.cfm"
    tier: 1
    used_for: "Primary recall notice — verify lot numbers and manufacturer"
  - publisher: "EatingWell"
    url: "https://www.eatingwell.com/the-fda-issued-a-recall-on-blood-pressure-medication-nationwide"
    tier: 2
    used_for: "Secondary confirmation of nationwide scope"
  - publisher: "CDC — High Blood Pressure"
    url: "https://www.cdc.gov/bloodpressure/index.htm"
    tier: 1
    used_for: "Hypertension prevalence data"
```

**Expert type needed:** Cardiologist or clinical pharmacist for guidance on what patients should do vs. should not do (e.g., don't self-discontinue).

**SEO:**
```yaml
primary_keyword: "chlorthalidone recall"
supporting_keywords: ["blood pressure medication recall 2026", "FDA drug recall", "chlorthalidone FDA", "hypertension medication recall", "what to do if your medication is recalled"]
format: "Breaking news + patient guidance"
schema_markup: "NewsArticle + FAQPage"
estimated_word_count: "800–1,100"
```

**Next steps:** Verify FDA MedWatch notice for specific manufacturer and lot codes immediately. Confirm recall reason (likely nitrosamine/carcinogen). Assign to writer now. Publish within 4 hours.

---

### BRIEF 3 — P1 / IMMEDIATE

```yaml
priority_level: P1
publish_timing: immediate
topic: "Retatrutide Phase 3: 30% Body Weight Loss, On Par With Bariatric Surgery"
primary_entity: "retatrutide"
signal_type: clinical_trial
allowed_category: "medical research and clinical trials"
trend_strength_score: 82
opportunity_score: 85
discover_score: 5
urgency: today
confidence: high
content_status: new
source_count: 5
recommended_angle: "Is retatrutide the drug that makes weight-loss surgery optional? What 30% weight loss in a trial actually means for patients"
why_now: "GLP-1/weight loss is one of the highest sustained interest categories (weight_loss Google Trends at 50, fitness rising); retatrutide's Phase 3 results showing 30% body weight loss — a figure comparable to bariatric surgery — is the most significant weight-loss drug result in years. First direct surgical comparison in coverage creates a differentiation opportunity."
primary_headline: "Retatrutide Helped People Lose 30% of Their Body Weight. Is This the Future of Obesity Treatment?"
```

**Alternate headlines:**
- "A New Weight-Loss Drug May Rival Bariatric Surgery — Here's What the Phase 3 Trial Found"
- "Beyond Ozempic: Retatrutide's 30% Weight Loss Result Just Changed the Conversation"

**Why now:** Phase 3 results published. The surgical-equivalence angle is the most compelling health story in the GLP-1 space since Wegovy approval. Weight loss search velocity remains strong and rising queries include sustained audience interest (jelly roll weight loss, baking soda TikTok trends show active weight loss audience).

**Angle:** Evidence-based explainer + patient implications. Don't hype it — contextualize it. 30% weight loss sounds extraordinary; the story is what that means at the biological level, what side effects look like, and where this sits in the approval pipeline.

**Integrity flags:**
- ⚠️ Phase 3 results reported via UCHealth and trade sources — verify the peer-reviewed journal publication (NEJM or equivalent) before citing trial data as final. DOI not directly retrieved.
- ⚠️ "On par with weight-loss surgery" framing is from press coverage, not the primary trial language — use "comparable outcomes reported in Phase 3" and specify the primary endpoint.
- ⚠️ Retatrutide is NOT yet FDA-approved — must be clearly stated. Do not imply availability.
- ⚠️ Triple agonist mechanism (GIP/GLP-1/glucagon) — distinguish from dual agonists (tirzepatide) and single agonists (semaglutide) to avoid conflating the drug class.

**Outline:**
1. **What happened** — Phase 3 trial results; what 30% body weight loss means (average starting weight, time period)
2. **What retatrutide is** — triple agonist, how it differs from Ozempic (GLP-1 only) and Mounjaro (GLP-1/GIP)
3. **The surgical comparison** — what bariatric surgery typically achieves; why 30% is significant
4. **Side effects** — what the Phase 3 trial showed (GI effects, nausea profile, tolerability)
5. **Where it is in approval** — Phase 3 complete; FDA submission timeline expected
6. **Who could benefit** — obesity criteria, comorbidities
7. **What this means for the field** — cost projections, access questions, how it fits alongside surgery and existing GLP-1s
8. **Expert context** — cite named researcher from trial or endocrinologist commentary

**Key data points:**
- 30% body weight loss (average, Phase 3)
- Bariatric surgery typically achieves 25–35% excess weight loss (cite ASMBS data)
- Retatrutide = GIP + GLP-1 + glucagon triple agonist (Eli Lilly)
- ~42% of US adults have obesity (CDC)

**Sources:**
```yaml
sources:
  - publisher: "UCHealth — Retatrutide Phase 3 Coverage"
    url: "https://www.uchealth.org/today/retatrutide-the-newest-weight-loss-drug-helped-people-lose-30-of-body-weight-on-par-with-weight-loss-surgery/"
    tier: 2
    used_for: "Phase 3 results reporting"
  - publisher: "NEJM (verify DOI for Eli Lilly TRIUMPH-3 or equivalent)"
    url: "[URL unverified — retrieve from PubMed before publish]"
    tier: 1
    used_for: "Primary trial data"
  - publisher: "CDC — Adult Obesity Prevalence"
    url: "https://www.cdc.gov/obesity/data/adult.html"
    tier: 1
    used_for: "Obesity prevalence context"
  - publisher: "American Society for Metabolic and Bariatric Surgery"
    url: "https://asmbs.org/resources/bariatric-surgery-fact-sheet"
    tier: 2
    used_for: "Surgical outcomes comparison"
```

**Expert type needed:** Endocrinologist or obesity medicine specialist; ideally a named researcher from the Eli Lilly trial or a commentary author in NEJM.

**SEO:**
```yaml
primary_keyword: "retatrutide weight loss"
supporting_keywords: ["retatrutide vs Ozempic", "new weight loss drug 2026", "retatrutide trial results", "triple agonist weight loss", "weight loss drug bariatric surgery comparison", "retatrutide FDA approval"]
format: "Explainer + FAQ"
schema_markup: "MedicalStudy + FAQPage"
estimated_word_count: "1,400–1,800"
```

**Next steps:** Retrieve primary NEJM publication and DOI before publish. Verify FDA submission status (Eli Lilly investor filings or FDA pipeline tracker). Assign to senior health writer with GLP-1 familiarity. Target publish within 24 hours.

---

### BRIEF 4 — P2 / SHORT-TERM

```yaml
priority_level: P2
publish_timing: short_term
topic: "Antidepressant Recall: Generic Duloxetine (Cymbalta) and Possible Carcinogen Risk"
primary_entity: "duloxetine recall"
signal_type: drug_or_treatment_claim
allowed_category: "FDA and CDC regulatory updates"
trend_strength_score: 78
opportunity_score: 77
discover_score: 4
urgency: today
confidence: medium
content_status: new
source_count: 3
recommended_angle: "What patients on duloxetine need to know: which generics are recalled, what the carcinogen risk actually means, and whether to keep taking your medication"
why_now: "Antidepressants are among the most widely prescribed medications in the US. A carcinogen contamination recall affecting a common generic creates immediate patient anxiety — and the dominant competitor coverage will be brief recall notices without clinical context."
primary_headline: "Generic Antidepressant Duloxetine Recalled Over Possible Carcinogen Risk: What Patients Should Do"
```

**Alternate headlines:**
- "Your Generic Cymbalta May Be Recalled. Here's What the Carcinogen Warning Means"
- "FDA Recalls Generic Duloxetine: The Questions Patients on Antidepressants Are Asking Right Now"

**Integrity flags:**
- ⚠️ Breaking-recall exception applied — verify specific manufacturer and lot codes at FDA MedWatch before publishing.
- ⚠️ "Possible carcinogen" language must be precise: specify classification (NDMA = IARC Group 2A probable carcinogen; not confirmed human carcinogen). Do not use "cancer-causing" without qualification.
- ⚠️ CRITICAL: Do NOT advise patients to stop taking duloxetine without medical guidance. Abrupt SNRI discontinuation causes withdrawal syndrome (discontinuation syndrome) which can be severe.
- ⚠️ Overstatement risk: MedShadow headline framing may conflate the contamination risk with confirmed cancer outcome — lead with actual risk framing from FDA classification.

**Outline:**
1. **What happened** — which generic duloxetine manufacturer(s), lot codes, recall class
2. **What duloxetine is** — SNRI antidepressant; also prescribed for anxiety, nerve pain, fibromyalgia
3. **The carcinogen concern explained** — nitrosamine contamination pattern (link to valsartan precedent); what "possible carcinogen" actually means at trace levels
4. **SNRI discontinuation warning** — why stopping abruptly is dangerous; must taper under medical supervision
5. **What to do today** — check lot number, call prescriber, pharmacist guidance
6. **What the FDA says** — actual recall classification language
7. **Broader context** — nitrosamine contamination in generic drugs; FDA's ongoing NDMA monitoring program

**Sources:**
```yaml
sources:
  - publisher: "FDA MedWatch — Drug Recalls"
    url: "https://www.accessdata.fda.gov/scripts/med/index.cfm"
    tier: 1
    used_for: "Primary recall notice — manufacturer, lots, classification"
  - publisher: "Health.com — FDA Announces Recall of Popular Antidepressant"
    url: "https://www.health.com/fda-announces-recall-of-popular-antidepressant-over-possible-carcinogen-risk"
    tier: 2
    used_for: "Secondary recall reporting"
  - publisher: "MedShadow Foundation"
    url: "https://medshadow.org/fda-recalls-and-warnings-gas-x-contaminated-with-coolant-more-generic-cymbalta-cancer-risks"
    tier: 2
    used_for: "Corroboration; editorial note on framing overstatement"
```

**Expert type needed:** Clinical pharmacist or psychiatrist for discontinuation syndrome guidance and contamination risk contextualization.

**SEO:**
```yaml
primary_keyword: "duloxetine recall"
supporting_keywords: ["generic Cymbalta recall", "antidepressant recall 2026", "duloxetine carcinogen", "NDMA drug recall", "what to do if antidepressant recalled"]
format: "Breaking news + patient guidance"
schema_markup: "NewsArticle + FAQPage"
estimated_word_count: "900–1,200"
```

**Next steps:** Verify FDA notice for specific manufacturer and lot codes. Confirm contamination class (NDMA vs. other nitrosamine). Publish within 48 hours — same-day competitor coverage will be thin on clinical context.

---

### BRIEF 5 — P2 / SHORT-TERM

```yaml
priority_level: P2
publish_timing: short_term
topic: "Shingles Vaccine Associated With Lower Dementia Risk — New Study"
primary_entity: "shingles vaccine dementia risk"
signal_type: medical_study
allowed_category: "aging and longevity"
trend_strength_score: 72
opportunity_score: 78
discover_score: 5
urgency: today
confidence: medium
content_status: new
source_count: 3
recommended_angle: "The study showing shingles vaccination is linked to lower dementia risk — what it actually found, what it can and can't prove, and whether you should get vaccinated if you haven't already"
why_now: "Published 06/15 via Brown University citing Annals of Internal Medicine. Dementia prevention is one of the highest-value search topics for 50+ health-conscious readers. The herpes zoster–dementia biological hypothesis is well-established, making this finding credible and extensible. Strong Discover score: specific named entity + durable question (does shingles vaccine prevent dementia?) with an existing SERP gap for quality consumer-facing explainers."
primary_headline: "Getting the Shingles Vaccine May Lower Your Dementia Risk, New Study Suggests"
```

**Alternate headlines:**
- "Should You Get the Shingles Vaccine? A New Study Links It to Lower Dementia Risk"
- "Shingrix and Dementia Risk: What a New Study Tells Us — and What It Doesn't"

**Integrity flags:**
- ⚠️ Observational study — cannot establish causation; must frame as association throughout.
- ⚠️ DOI not directly retrieved — confirm primary publication in Annals of Internal Medicine before citing specific effect sizes or confidence intervals.
- ⚠️ Do not frame as "vaccine prevents dementia" — frame as "vaccination associated with lower risk in observational data."
- ⚠️ Confidence capped Medium until primary AIM publication confirmed.

**Outline:**
1. **The finding** — what the study found, magnitude of risk reduction (retrieve from AIM paper)
2. **What the study was** — observational, population-level; how designed; size; duration
3. **The biological hypothesis** — herpes zoster virus and neuroinflammation; varicella-zoster reactivation and Alzheimer's pathology (existing literature)
4. **What this doesn't prove** — correlation vs. causation; confounders (healthy vaccinee bias)
5. **Current shingles vaccine recommendations** — Shingrix (recombinant, 2-dose), CDC recommendation: adults 50+
6. **Should you get vaccinated?** — independent of this study, why Shingrix is already recommended; this data adds potential further reason
7. **What researchers say next** — need for RCT; ongoing studies

**Sources:**
```yaml
sources:
  - publisher: "Brown University — Study Suggests Shingles Vaccine May Lower Dementia Risk"
    url: "https://news.brown.edu/articles/2026/06/shingles-vaccine-dementia"
    tier: 2
    used_for: "Press release; secondary confirmation of study"
  - publisher: "Annals of Internal Medicine (verify DOI)"
    url: "[URL unverified — retrieve from PubMed before publish]"
    tier: 1
    used_for: "Primary study data, effect sizes"
  - publisher: "CDC — Shingles Vaccination"
    url: "https://www.cdc.gov/shingles/vaccination/index.html"
    tier: 1
    used_for: "Current vaccination recommendations"
```

**Expert type needed:** Geriatrician or neurologist with dementia/neuroprotection focus; or named researcher from the Brown study.

**SEO:**
```yaml
primary_keyword: "shingles vaccine dementia risk"
supporting_keywords: ["Shingrix dementia", "shingles vaccine benefits over 50", "can shingles vaccine prevent dementia", "herpes zoster dementia", "shingles vaccination Alzheimer's"]
format: "Research explainer + patient Q&A"
schema_markup: "MedicalStudy + FAQPage"
estimated_word_count: "1,200–1,500"
```

**Next steps:** Retrieve AIM publication DOI from PubMed. Confirm effect size and study design. Assign to health writer with aging/longevity familiarity. Publish within 48 hours — early competitor coverage will be thin on mechanism explanation.

---

### BRIEF 6 — P2 / SHORT-TERM

```yaml
priority_level: P2
publish_timing: short_term
topic: "Mental Health and Pregnancy Planning: What New Research Shows"
primary_entity: "mental health family planning"
signal_type: study_or_research
allowed_category: "mental health and psychology"
trend_strength_score: 65
opportunity_score: 72
discover_score: 4
urgency: this_week
confidence: high
content_status: new
source_count: 3
recommended_angle: "The mental health conversation that happens before pregnancy — what the NYT Well story surfaces, why this gap matters, and what patients and providers can do"
why_now: "NYT Well published 06/17 — within 24 hours. Mental health velocity is declining overall (-13 week on week) but this specific nexus — mental health + reproductive planning — is underserved in health content and addresses a high-anxiety audience question. Women's health + mental health = two core allowed categories intersecting."
primary_headline: "The Mental Health Factor in Pregnancy Planning That Most Doctors Don't Discuss"
```

**Alternate headlines:**
- "Planning a Pregnancy? Your Mental Health History Matters More Than You Think"
- "Why Mental Health Should Be Part of Every Family Planning Conversation"

**Integrity flags:**
- ⚠️ Primary research source behind NYT Well story not directly retrieved — verify underlying study or data before citing specific statistics.
- ⚠️ Do not overstate psychiatric medication risk in pregnancy without citing current ACOG guidance — risks of stopping medication often outweigh risks of continuing.
- ⚠️ Frame psychiatric medication in pregnancy as a clinical nuance conversation, not a scare story.

**Outline:**
1. **The gap** — what the NYT Well piece surfaces: mental health history is rarely part of preconception care
2. **Why it matters** — peripartum depression/anxiety; psychiatric medication decisions during pregnancy; history of trauma and birth outcomes
3. **What the research shows** — cite underlying study (retrieve from NYT Well links)
4. **The medication question** — the real risk calculus: untreated depression vs. medication exposure
5. **What to ask your doctor before trying to conceive** — specific, actionable checklist
6. **Resources** — Postpartum Support International, ACOG guidance, maternal mental health clinics

**Sources:**
```yaml
sources:
  - publisher: "The New York Times — Well"
    url: "https://www.nytimes.com/2026/06/17/well/mental-health-family-planning-pregnancy.html"
    tier: 1
    used_for: "Primary signal source; retrieve linked studies from article"
  - publisher: "ACOG — Mental Health and Pregnancy"
    url: "https://www.acog.org/womens-health/faqs/mental-health-during-pregnancy"
    tier: 1
    used_for: "Clinical guidance on psychiatric conditions in pregnancy"
  - publisher: "Postpartum Support International"
    url: "https://www.postpartum.net/"
    tier: 2
    used_for: "Patient resources"
```

**Expert type needed:** OB/GYN with maternal mental health focus or perinatal psychiatrist.

**SEO:**
```yaml
primary_keyword: "mental health pregnancy planning"
supporting_keywords: ["preconception mental health", "antidepressants pregnancy planning", "depression and pregnancy", "mental health before pregnancy", "peripartum depression risk"]
format: "Explainer + actionable checklist"
schema_markup: "Article + FAQPage"
estimated_word_count: "1,200–1,500"
```

**Next steps:** Read NYT Well article in full; retrieve underlying research. Consult ACOG guidelines on psychiatric conditions in pregnancy. Assign to writer with women's health experience. Target 48–72 hours.

---

### BRIEF 7 — P2 / SHORT-TERM

```yaml
priority_level: P2
publish_timing: short_term
topic: "GLP-1 Drug Associated With Slower Biological Aging — What the Study Actually Says"
primary_entity: "GLP-1 biological aging"
signal_type: medical_study
allowed_category: "aging and longevity"
trend_strength_score: 70
opportunity_score: 70
discover_score: 4
urgency: today
confidence: medium
content_status: new
source_count: 3
recommended_angle: "What 'slowing biological aging' actually means — and why the GLP-1 aging study is being misread by almost everyone covering it"
why_now: "UC study published recently; GLP-1 continues to be one of the highest-sustained search topics. The 'aging' angle is newer than weight loss coverage and opens a distinct content cluster (longevity + GLP-1). Opportunity is in correcting the coverage: most stories will say 'GLP-1 reverses aging' — this angle says 'here's what epigenetic clocks actually measure and what this study can and can't claim.'"
primary_headline: "GLP-1 Drugs May Slow Biological Aging — But What Does That Actually Mean?"
```

**Alternate headlines:**
- "New Study Links Ozempic-Class Drugs to Slower Biological Aging. Scientists Say Read the Fine Print."
- "The GLP-1 and Aging Study: What It Found, and What the Headlines Got Wrong"

**Integrity flags:**
- ⚠️ "Slowing biological aging" in press coverage likely refers to epigenetic clock markers (e.g., GrimAge, PhenoAge) — not direct longevity outcomes. Must specify the measure used.
- ⚠️ Correlation, not causation — observational study on biomarkers, not lifespan data.
- ⚠️ Mechanism not established — weight loss itself reduces aging biomarkers; whether GLP-1 has independent aging effects is not confirmed.
- ⚠️ Do not generalize to "GLP-1 is anti-aging medication" — this language is common in coverage and is unsupported.
- ⚠️ Primary UC publication not directly retrieved — verify journal and DOI before citing specific findings.

**Outline:**
1. **What the study found** — which GLP-1 drug, what aging markers were measured, magnitude of change
2. **What "biological age" means** — epigenetic clocks, methylation markers; what they measure vs. what they don't
3. **Why this is interesting** — if confirmed, GLP-1 effects may extend beyond metabolic health; mechanisms (inflammation reduction, metabolic improvement)
4. **What it doesn't prove** — can't claim longer life from a biomarker study; confounders; obesity itself accelerates aging so weight loss alone explains some effect
5. **Where this sits in the GLP-1 landscape** — beyond weight loss and diabetes: cardiovascular (SEMA-3), kidney (FLOW trial), now aging research
6. **What experts say** — cite named researcher from UC study or longevity researcher commentary

**Sources:**
```yaml
sources:
  - publisher: "University of California — GLP-1 Biological Aging Study"
    url: "https://www.universityofcalifornia.edu/news/new-study-shows-popular-glp-1-weight-loss-drug-may-slow-biological-aging"
    tier: 2
    used_for: "Press release; secondary source for study overview"
  - publisher: "Primary journal publication (verify DOI)"
    url: "[URL unverified — retrieve from PubMed before publish]"
    tier: 1
    used_for: "Primary study data and methodology"
  - publisher: "NIH — Biological Aging Research"
    url: "https://www.nia.nih.gov/research/labs/lmbi/epigenetic-aging"
    tier: 1
    used_for: "Context on epigenetic aging measurement"
```

**Expert type needed:** Geroscientist or aging researcher familiar with epigenetic clocks; or the named UC researcher.

**SEO:**
```yaml
primary_keyword: "GLP-1 biological aging"
supporting_keywords: ["Ozempic aging study", "semaglutide anti-aging", "GLP-1 longevity", "biological age and weight loss", "epigenetic clock GLP-1"]
format: "Research explainer with skeptical angle"
schema_markup: "MedicalStudy + Article"
estimated_word_count: "1,200–1,600"
```

**Next steps:** Retrieve primary publication and DOI. Confirm what aging marker was used. Assign to writer comfortable with nuanced mechanism stories. Target 48 hours.

---

### BRIEF 8 — P3 / SCHEDULED

```yaml
priority_level: P3
publish_timing: scheduled
topic: "Psilocybin for Mental Health: USC Launches First Clinical Trial"
primary_entity: "psilocybin USC clinical trial"
signal_type: clinical_trial
allowed_category: "mental health and psychology"
trend_strength_score: 60
opportunity_score: 65
discover_score: 3
urgency: this_week
confidence: high
content_status: new
source_count: 2
recommended_angle: "What USC's psilocybin trial could mean for treatment-resistant depression — and what's different about this study"
why_now: "USC Keck School of Medicine launched the institution's first psilocybin clinical study this week (06/16). Psilocybin mental health is one of the fastest-growing research areas in psychiatry, with sustained audience interest in psychedelic therapy."
primary_headline: "USC Just Launched Its First Psilocybin Study for Mental Health. Here's What It's Testing."
```

**Integrity flags:**
- ⚠️ This is a trial launch, not trial results — frame as "researchers are studying," not "psilocybin works for X."
- ⚠️ Distinguish from FDA Breakthrough Therapy designation context; clarify regulatory status.
- ⚠️ Do not conflate recreational use with clinical psilocybin therapy protocols.

**Key data points:** USC Keck funding received 06/16; trial focus area (retrieve from USC press release); existing psilocybin evidence base: COMPASS Pathways Phase 2b, NYU and Johns Hopkins trials.

**Sources:**
```yaml
sources:
  - publisher: "Keck School of Medicine of USC"
    url: "https://keck.usc.edu/news/researchers-receive-funding-to-launch-uscs-first-clinical-study-of-psilocybin-for-mental-health/"
    tier: 2
    used_for: "Primary announcement"
  - publisher: "ClinicalTrials.gov (search: psilocybin USC)"
    url: "https://clinicaltrials.gov/search?term=psilocybin+USC"
    tier: 1
    used_for: "Trial registration and protocol"
```

**SEO:** `primary_keyword: "psilocybin clinical trial"` | Format: News explainer | Word count: 900–1,100

**Next steps:** Retrieve trial registration from ClinicalTrials.gov. Clarify specific indication and patient population. Schedule within 5 days.

---

### BRIEF 9 — P3 / SCHEDULED

```yaml
priority_level: P3
publish_timing: scheduled
topic: "NIH: Lifestyle Intervention in Prediabetes Lowers Risk of Multiple Chronic Conditions"
primary_entity: "prediabetes lifestyle intervention"
signal_type: clinical_trial
allowed_category: "chronic disease management"
trend_strength_score: 58
opportunity_score: 68
discover_score: 4
urgency: this_week
confidence: high
content_status: new
source_count: 3
recommended_angle: "The prediabetes intervention plan — backed by a new NIH study — that protects against heart disease, kidney disease, and more at the same time"
why_now: "NIH published 06/15 — within 72 hours. Prediabetes affects ~98 million US adults. The multi-condition protective effect (rather than just diabetes prevention) is the differentiating finding and the content gap — most coverage will lead with diabetes prevention alone."
primary_headline: "If You Have Prediabetes, This Lifestyle Plan Can Cut Risk of Multiple Diseases, NIH Study Finds"
```

**Integrity flags:**
- ⚠️ Retrieve primary publication — confirm whether this is DPP (Diabetes Prevention Program) follow-up data or a new trial.
- ⚠️ Specify what "lifestyle intervention" means in the study — caloric targets, physical activity minutes, behavioral counseling — do not let it remain vague.
- ⚠️ Observational vs. RCT: note study design and limitations.

**Key data points:** 98 million US adults with prediabetes (CDC); ~1 in 3 adults; NIH study published 06/15 via NIH.gov.

**Sources:**
```yaml
sources:
  - publisher: "NIH News Releases"
    url: "https://www.nih.gov/news-events/news-releases/adults-prediabetes-lifestyle-intervention-lowered-risk-developing-multiple-chronic-conditions"
    tier: 1
    used_for: "Primary institutional source"
  - publisher: "CDC — Prediabetes"
    url: "https://www.cdc.gov/diabetes/basics/prediabetes.html"
    tier: 1
    used_for: "Prevalence data and screening guidance"
```

**SEO:** `primary_keyword: "prediabetes lifestyle intervention"` | Format: Research explainer + actionable guide | Word count: 1,100–1,400

**Next steps:** Pull NIH press release and primary publication. Retrieve the exact intervention protocol from the study. Schedule within 5–7 days.

---

## REJECTED TOPICS LOG

| Topic | Rejection Reason | Source |
|---|---|---|
| Taylor Parker mental health diagnosis | Brand safety — criminal case celebrity angle; excluded category (celebrity gossip) | Google Trends rising |
| Jeremy Clarkson health / Mitch McConnell health / David Bromstad health | Celebrity health status speculation — excluded category | Google Trends rising |
| GetActive.gov / Secretary Kennedy Colorado tour | Political adjacency + brand safety flag; HHS political initiative | HHS.gov |
| KFF mental health policy tracker — Trump administration | Primarily political policy analysis; no new health science signal today | KFF |
| Google AMIE / LLM medical AI benchmarks | Tech/AI story; adjacent but not core health category; audience relevance moderate | Nature, blog.google |
| University of Michigan brain-computer interface | Highly specialized; niche audience; tech-adjacent medical device | Michigan Medicine |
| Novo Nordisk cyberattack / clinical trial data stolen | Cybersecurity story, not health content | HIPAA Journal |
| GLP-1 lifetime cost savings ($192K) | Business/economics framing; editorial overlap with retatrutide brief; deferred | Fortune |
| Mount Sinai music therapy cancer study | Single small study, no primary publication retrieved, low search velocity | Florida Hospital News |
| Mac & cheese recall (525K packages) | Subsumed into Alfredo sauce recall brief context; can be added as sidebar |KSNT / Audacy |
| Birth control drug recall (3 drugs) | Insufficient corroboration — The Healthy only; verify before publishing; Monitored | The Healthy |
| Infant formula recall | fda.gov homepage signal without specific recall notice details; Monitored pending verification | Prevention, FDA |
| Gas-X coolant contamination | Included in MedShadow omnibus; lower individual urgency; deferred | MedShadow |
| Hypothyroidism new treatment (UConn) | Single institutional source; insufficient corroboration; Monitored | UConn Today |
| Melanoma / moles genetic study | Retained below — see Monitor note; SERP difficulty high; deferred to P5 | Medical Xpress |
| Pew abortion data | Excluded category — political/social policy | Pew Research |
| CaroMont new hospital, Northwestern grant | Local/institutional; too narrow for national health audience | CaroMont Health, Northwestern |
| Wellness retreats, Father's Day wellness gifts | Off-category lifestyle fluff | Oprah Daily, Forbes |
| Global Wellness Day 2026 | Low informational value; seasonal marketing event | Google Trends |
| Banfield wellness plan / pet death | Off-category (pet health) | CBS News |
| Gallup healthcare affordability | Policy/economics; good evergreen angle; no fresh editorial hook today — deferred | Gallup |
| CMS health technology office | B2B/institutional; not audience-relevant | Healthcare Dive |
| AI transforming clinical trial recruitment | B2B clinical trial operations; not patient-facing | Business Journals |
| Sourdough vs white bread nutrition | Rising search query but no news anchor; pure SEO topic — route to evergreen queue | Google Trends |
| Baking soda weight loss TikTok queries | Social-only signal; unverified health claim; brand safety fail | Google Trends |
| All local wellness events, community health announcements | Off-category — too local/narrow | Various |

---

## INTEGRITY FLAGS — CONSOLIDATED

All ⚠️ flags for editorial review before publishing:

| Brief | Flag |
|---|---|
| **All recalls (Briefs 1, 2, 4)** | Breaking-recall exception applied — verify full FDA notice (manufacturer, lot codes, UPC) at FDA.gov / FDA MedWatch before publishing any brief |
| **Brief 1 — Alfredo sauce** | Verify complete lot code list from FDA recall page; do not publish product names without FDA confirmation |
| **Brief 2 — Chlorthalidone** | Do not advise stopping medication without physician guidance; abrupt antihypertensive discontinuation is dangerous |
| **Brief 3 — Retatrutide** | Retrieve NEJM primary publication DOI; confirm "30% weight loss" is primary endpoint; clearly state NOT yet FDA-approved |
| **Brief 3 — Retatrutide** | "On par with surgery" is press framing, not trial language — use "comparable to outcomes reported for bariatric surgery in separate literature" |
| **Brief 4 — Duloxetine** | CRITICAL: do not advise stopping antidepressant without taper plan; SNRI discontinuation syndrome is serious |
| **Brief 4 — Duloxetine** | Distinguish "probable carcinogen" (IARC 2A) from "known carcinogen" or "will cause cancer" |
| **Brief 5 — Shingles/dementia** | Observational study only — must frame as association throughout; retrieve AIM DOI |
| **Brief 6 — Mental health/pregnancy** | Do not frame psychiatric medication in pregnancy as simply dangerous; cite ACOG guidance on risk-benefit |
| **Brief 7 — GLP-1 aging** | "Biological aging" = epigenetic marker, not lifespan; do not use "reverses aging"; retrieve primary publication and confirm which aging clock was used |
| **Brief 8 — Psilocybin** | Trial launch, not results — frame as "researchers are studying" |
| **Brief 9 — Prediabetes** | Confirm whether this is DPP follow-up or new trial; specify intervention protocol precisely |

---

## RUN NOTES

```yaml
run_date: 2026-06-18
niche: "health and wellness"
signals_reviewed: 144
topics_retained: 9
topics_rejected: ~135 (including monitored/deferred)
p1_count: 3
p2_count: 4
p3_count: 2
p5_monitor_count: 5 (birth control recall, infant formula recall, Gallup affordability, hypothyroidism UConn, melanoma/moles study)
integrity_flags: 14
top_topic: "Alfredo Sauce Salmonella Recall — FDA Class I, 41 States"
key_themes:
  - FDA food and drug recalls (dominant cluster — 4 independent recalls across food and pharmaceutical)
  - GLP-1 / weight loss drug developments (retatrutide trial results, aging study)
  - Mental health (pregnancy planning, psilocybin trial)
  - Aging and longevity (shingles/dementia, GLP-1 aging)
  - Chronic disease prevention (prediabetes NIH intervention)
tools_used:
  - SerpAPI Google Trends (injected pre-fetch — 7-day interest + Trending Now)
  - SerpAPI Google News (injected — 144 headlines across 12 queries)
tools_unavailable: []
google_trends_available: true
google_trends_tool: "serpapi_prefetch"
search_velocity_source: "google_trends"
site_url_configured: false
self_check_method: "competitor-check fallback (competitor_list.yaml)"
deferred_topics_file: "not found — treated as empty"
run_history_file: "not found — staleness check not possible"
dashboard_output: "outputs/daily_newsroom_dashboard/2026-06-18.html"
notes: >
  Recall cluster is unusually dense today — 8+ distinct FDA recalls active simultaneously across
  food and pharmaceuticals. This appears to be genuine regulatory activity, not a coverage spike.
  Prioritized the two with highest search velocity and consumer action need (Alfredo sauce Class I,
  chlorthalidone Trending Now). Duloxetine recall also high priority for mental health audience.
  
  Birth control recall (The Healthy) and infant formula recall (Prevention) are Monitored at P5 —
  insufficient independent corroboration to publish without verifying FDA notice directly.
  Recommend checking FDA.gov manually before next run.
  
  GLP-1 remains the dominant research theme — retatrutide's Phase 3 results are the most
  actionable single research story. The aging angle (Brief 7) is differentiated from weight
  loss coverage but requires strong editorial discipline on mechanism language.
  
  Mental health velocity is declining week-over-week (-13) but individual story hooks are strong
  (NYT Well pregnancy piece, USC psilocybin trial). Not a fading topic — declining from a
  recent spike, not trending toward irrelevance.
  
  No deferred topics or run history to compare — first run in this environment. Recommend
  establishing data/run_history.yaml and data/deferred_topics.yaml files after this run.
```

---

*Pipeline complete. 9 candidates retained across P1–P3. 3 immediate-publish briefs ready for editorial review pending FDA notice verification. All source links included where retrievable; [URL unverified] flagged where DOIs require manual PubMed lookup before publish.*